(+)-JQ1

Catalog No.S7110

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Cited by 70 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(2):271-285.e7

PubMed: 30107177 ( click the link to review the publication )

Nat Med, 2017, 23(4):493-500

PubMed: 28263307 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Gastroenterology, 2014, 147(5):1119-33

PubMed: 25127677 ( click the link to review the publication )

Sci Transl Med, 2019, 11(497)

PubMed: 31217338 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(2)

PubMed: 30610113 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Cancer Res, 2019, 79(9):2415-2425

PubMed: 30885979 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Theranostics, 2019, 9(13):3840-3852

PubMed: 31281517 ( click the link to review the publication )

J Hematol Oncol, 2019, 12(1):73

PubMed: 31288832 ( click the link to review the publication )

Redox Biol, 2019, 24:101195

PubMed: 31004990 ( click the link to review the publication )

Cancer Lett, 2019, 442:373-382

PubMed: 30419347 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Addict Biol, 2019, 10.1111/adb.12808

PubMed: 31364211 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):2111-2123

PubMed: 31467179 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

J Thorac Cardiovasc Surg, 2019, 10.1016/j.jtcvs.2019.06.115

PubMed: 31564537 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13305

PubMed: 31527644 ( click the link to review the publication )

Biomed Pharmacother, 2019, 114:108793

PubMed: 30921702 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 519(3):481-488

PubMed: 31530390 ( click the link to review the publication )
J Oral Pathol Med, 2019, 10.1111/jop.12906

PubMed: 31177574 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):499-507

PubMed: 30483785 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2340-2347

PubMed: 31452730 ( click the link to review the publication )

Journal of Oral Pathology & Medicine, 2019, 10.1111/jop.12906

PubMed: 无 ( click the link to review the publication )

J Am Soc Nephrol, 2018, 29(6):1690-1705

PubMed: 29739813 ( click the link to review the publication )

Cell Rep, 2018, 22(8):2016-2025

PubMed: 29466730 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Oncogene, 2018, 37(28):3763-3777

PubMed: 29636547 ( click the link to review the publication )

Clin Epigenetics, 2018, 10:01

PubMed: 29312470 ( click the link to review the publication )

Exp Mol Med, 2018, 50(1):e419

PubMed: 29303513 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 50(2):798-809

PubMed: 30308485 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Gynecol Oncol, 2018, 149(3):575-584

PubMed: 29567272 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Int J Oncol, 2018, 53(6):2503-2517

PubMed: 30272279 ( click the link to review the publication )

Int J Stem Cells, 2018, 11(1):131-140

PubMed: 29699387 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 499(3):531-537

PubMed: 29596834 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(4):931-940

PubMed: 28750570 ( click the link to review the publication )

Leuk Lymphoma, 2018, 59(5):1248-1251

PubMed: 28885069 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(15):4462-4472

PubMed: 28270499 ( click the link to review the publication )

Cancer Res, 2017, 77(20):5564-5575

PubMed: 28819026 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )
Biochim Biophys Acta Mol Basis Dis, 2017, 1863(12):3001-3015

PubMed: 28844955 ( click the link to review the publication )

Org Biomol Chem, 2017, 15(44):9352-9361

PubMed: 29087414 ( click the link to review the publication )

Biomed Pharmacother, 2017, 95:1574-1579

PubMed: 28950657 ( click the link to review the publication )

Cell Biosci, 2017, 7:56

PubMed: 29118968 ( click the link to review the publication )

Biol Res, 2017, 50(1):19

PubMed: 28545522 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86312-86324

PubMed: 29156797 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51402-51415

PubMed: 28881656 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98471-98481

PubMed: 29228703 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16646

PubMed: 29192216 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2448

PubMed: 27401245 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0750

PubMed: 26939702 ( click the link to review the publication )

Oncol Rep, 2016, 36(4):1989-96

PubMed: 27573714 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 469(3):679-85

PubMed: 26707881 ( click the link to review the publication )

Oncotarget, 2016, 6(7):5134-46

PubMed: 25762617 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6576-92

PubMed: 26536665 ( click the link to review the publication )

Sci Rep, 2016, 6:23770

PubMed: 27044328 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1034416

PubMed: 25941994 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Exp Ther Med, 2015, 10(6):2319-2324

PubMed: 26668635 ( click the link to review the publication )

Cancer Res, 2014, 74(23):7090-102

PubMed: 25277525 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description

Features

(+)-JQ1 is more effective than (-)-JQ1.

Targets

BRD4 (2) ^[1] (Cell-free assay)	BRD4 (1) ^[1] (Cell-free assay)
33 nM	77 nM

In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. ^[1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. ^[2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. ^[3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
K1	MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NUPSZm1EOjVyL{WwNE8yODByIH7N	MUGyOE81QC95MjDo	NULFWY57TE2VTx?=	NEPsW4NqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	M4PHTFI3PzB5OEix
BCPAP	M3v2[WNmdGxiVnnhZoltcXS7IFHzd4F6	NX;0e\|Z1OjVyL{WwNE8yODByIH7N	NXzITohROjRxNEivO\|IhcA>?	MYLEUXNQ	NH;peXpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz	MXuyOlcxPzh6MR?=
K1	MnfmR4VtdCCFeXPs[UBCe3OjeR?=	NFzs[VEzPTBxNUCwM\|ExODBibl2=	NYL2[3c4PzJiaB?=	M3nySmROW09?	MWThdpJme3S\|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V?	NHPhNYIzPjdyN{i4NS=>
BCPAP	M3rhcWNmdGxiQ4njcIUhSXO\|YYm=	M2fLflI2OC93MECvNVAxOCCwTR?=	MV:3NkBp	NWLXNY0xTE2VTx?=	MVXhdpJme3S\|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V?	M332e\|I3PzB5OEix
Hep3B	M17tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXwcoY4OC1zMDFOwG0>	MWC1JIQ>	MULEUXNQ	M3vrT2lEPTB;MD6wPEDPxE1?	NUTubmpEOjZ3N{WxOlc>
HCCLM3	MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfvbHpPOC1zMDFOwG0>	NX;5XnYxPSCm	NYPGc4UyTE2VTx?=	M4fqemlEPTB;MD6xOEDPxE1?	NWfJXGpoOjZ3N{WxOlc>
HuH7	NHPhe4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn70NE0yOCEQvF2=	NEHzSZc2KGR?	NHXObIZFVVOR	MWrJR\|UxRTBwMkGg{txO	MmHFNlY2PzVzNke=
HepG2	M2rU[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXqwMVExKM7:TR?=	MYG1JIQ>	M3XpVWROW09?	MkTVTWM2OD1yLkO0JO69VQ>?	MkPPNlY2PzVzNke=
SMMC7721	NHTtTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfjNE0yOCEQvF2=	MlGzOUBl	MWDEUXNQ	NGHhOlBKSzVyPUCuOFEh\|ryP	MVmyOlU4PTF4Nx?=
BEL7402	MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TUWlAuOTBizszN	MXy1JIQ>	MUXEUXNQ	MYjJR\|UxRTBwNEeg{txO	NIruRWMzPjV5NUG2Oy=>
MHCC97H	M3TKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\sT5pHOC1zMDFOwG0>	NV7aVIlWPSCm	MYHEUXNQ	NYT2ZVU{UUN3ME2wMlQyKM7:TR?=	MX:yOlU4PTF4Nx?=
Hep3B	M1LXWmNmdGxiQ4njcIUhSXO\|YYm=	NH7IVIsxNjFxMD61M\|IvPSEQvF2=	NGLid2w1QCCq	M4X4cGROW09?	MXHs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA>	MVOyOlU4PTF4Nx?=
HCCLM3	NE\hbo1E\WyuIFP5Z4xmKEG\|c3H5	NIO3PZQxNjFxMD61M\|IvPSEQvF2=	MW[0PEBp	NFLMcpVFVVOR	MojXcIVi\HNidH:gZUB{fWK\|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhUEOFIHPlcIx{KGmwIIP1Zk1IOSCyaHHz[eKh	M{j6WFI3PTd3MU[3
Hep3B	MlnmRZBweHSxc3nzJGF{e2G7	MorCNE4yNzBwNT:yMlUh\|ryP	Ml;HOFghcA>?	MUPEUXNQ	NXrSS21z[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG\|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG\|bTDmdo9uKG2rdH;jbI9v\HKrYR?=	NWHjZ3h[OjZ3N{WxOlc>
HCCLM3	M{TFXmFxd3C2b4Ppd{BCe3OjeR?=	MYqwMlEwOC53L{KuOUDPxE1?	NVzqbGMzPDhiaB?=	NX3rTlMxTE2VTx?=	NF7WdJJi[3SrdnH0[ZMh[2G\|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW\|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj	NW\aTWdCOjZ3N{WxOlc>
A549	NEnRfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn4NE4yNTFyIN88US=>	M2r5N\|czKGh?		NWTxUY5xcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MUmyOlQyPTJ{NR?=
H157	NUPTN4ozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[wMlEuOTBizszN	MV63NkBp		MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MkjnNlY1OTV{MkW=
H1299	MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLwfno1OC5zLUGwJO69VQ>?	M1\3bVczKGh?		NX3p[o9IcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MkfUNlY1OTV{MkW=
A549	M33HSGZ2dmO2aX;uJGF{e2G7	MoTmNU8zNjVxNTFOwG0>	M4G5UVEzKGh?		Mnn1xsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>?	NHfBSogzPjRzNUKyOS=>
H1299	MYrGeY5kfGmxbjDBd5NigQ>?	M33IblEwOi53L{Wg{txO	MYCxNkBp		M4jkeuKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN?	M{\mOFI3PDF3MkK1
H157	NWfWeodwTnWwY4Tpc44hSXO\|YYm=	NHrFTWsyNzJwNT:1JO69VQ>?	M37zXlEzKGh?		NILlUpNl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36=	MVeyOlQyPTJ{NR?=
H1299	MnPpSpVv[3Srb36gRZN{[Xl?	NWTTcWppOS9{LkWvOUDPxE1?	NUmzcmUzOTJiaB?=		MlzU[IVkemWjc3XkJGRTPCCneIDy[ZN{cW:w	Mn\uNlY1OTV{MkW=
C8161	NGrGSHBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NF73[HExNTJizszN	MkHDOEBl	MoPCSG1UVw>?	M1jpR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFXpT4MzPjN7N{KyNy=>
Mel285	NGi0d\|BE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NWqye3ZyOC1{IN88US=>	MV[0JIQ>	NEG0PFZFVVOR	MmnB[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MX:yOlM6PzJ{Mx?=
Mel290	NILt[WdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M1;u[VAuOiEQvF2=	M{nE[\|Qh\A>?	MlzvSG1UVw>?	NVrC[3RC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M2XrOFI3Ozl5MkKz
92.1	NHjLR45E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	M3;Fe\|AuOiEQvF2=	MonrOEBl	NVXrdnJWTE2VTx?=	NILtVIJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NE[yXHozPjN7N{KyNy=>
Omm1.3	NGHVdItE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXuwZpFQOC1{IN88US=>	NHSxcXk1KGR?	M1izcGROW09?	M2XqfoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NXf3dVY{OjZ\|OUeyNlM>
Mel202	NWDOXlFmS2WubDDWbYFjcWyrdImgRZN{[Xl?	NHXpU5YxNTJizszN	MVu0JIQ>	NYTzUXF4TE2VTx?=	NHfFWI1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXTMTIpKOjZ\|OUeyNlM>
Mel270	MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NUTjWHU2OC1{IN88US=>	MoDLOEBl	M1mzfWROW09?	NETuSXpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NYDOcVVKOjZ\|OUeyNlM>
Omm1	NXLLWFFUS2WubDDWbYFjcWyrdImgRZN{[Xl?	MYewMVIh\|ryP	NV3kdXVwPCCm	MVrEUXNQ	NXjaeXN[\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MViyOlM6PzJ{Mx?=
92.1	MULBdI9xfG:\|aYOgRZN{[Xl?	M1XUW\|UxOCCwTR?=	MYi0PEBp	Mn;uSG1UVw>?	NHXEV3ZqdmS3Y3XzJIFxd3C2b4Ppdy=>	MUeyOlM6PzJ{Mx?=
Omm1.3	NHzj[GtCeG:ydH;zbZMhSXO\|YYm=	M1L6fVUxOCCwTR?=	NHG1Wpk1QCCq	NY\WTmxVTE2VTx?=	NWnwNYJEcW6mdXPld{BieG:ydH;zbZM>	M1HCNVI3Ozl5MkKz
92.1	NFzWV2NE\WyuIFP5Z4xmKEG\|c3H5	M2LhZlUxOCCwTR?=	Mmf5NlQwPDhxN{KgbC=>	M2fvXmROW09?	MkHsbY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB?	MVmyOlM6PzJ{Mx?=
Omm1.3	NVvMTHI4S2WubDDDfYNt\SCDc4PhfS=>	MUO1NFAhdk1?	NFH6SVUzPC92OD:3NkBp	M331WWROW09?	NFXKXnBqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?=	NYLLVGpWOjZ\|OUeyNlM>
A549	MYTGeY5kfGmxbjDBd5NigQ>?	Ml3FNVAxNzRyMD:xNFAxKG6P	M4eybFI1KGh?		MlrYeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>?	NFq1enAzPjJzMkG5PS=>
MCF-7	M2DEdmZ2dmO2aX;uJGF{e2G7	M4j6SVExOC92MECvNVAxOCCwTR?=	NIraUnkzPCCq		NGq5cmx2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz	M1\IXlI3OjF{MUm5
HEK293	NX\ZTpNwTnWwY4Tpc44hSXO\|YYm=	MXSxNFAwPDByL{GwNFAhdk1?	NXTsS5JlOjRiaB?=		MlPZeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>?	MkjsNlYzOTJzOUm=
858	M3TsT2NmdGxiVnnhZoltcXS7IFHzd4F6	NVy0cWxZOC1zIN88US=>	NVXnbY01PSCm	MVTEUXNQ	MkPv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MoHZNlYzODZ\|M{O=
DDR2L63V	MojVR4VtdCCYaXHibYxqfHliQYPzZZk>	Mn7aNE0yKM7:TR?=	NHvRUGo2KGR?	M1Tse2ROW09?	NHyy[ZBl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MVeyOlIxPjN\|Mx?=
BE(2)-C	NFzjfopE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MUixJO69VQ>?	M2[4RlEuPCCm		NVXGZ2c3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	M1HzS\|I3ODZ5NE[0
IMR-32	MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MUexJO69VQ>?	NE\SWGgyNTRiZB?=		NV\EW\|Bv\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	MlXNNlYxPjd2NkS=
JF	MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M4HQV\|Eh\|ryP	M{jnTlEuPCCm		NYOySZZK\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	NVj0Rox2OjZyNke0OlQ>
BE(2)-M17	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	Mmm0NUDPxE1?	M1y0VVEuPCCm		NWPY[4du\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl?	NFn5[mszPjB4N{S2OC=>
SK-N-SH	M2G4UmNmdGxiVnnhZoltcXS7IFHzd4F6	MXKxJO69VQ>?	NWTvdm1ROS12IHS=		M3vRUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6	NGD4SWczPjB4N{S2OC=>
SK-N-DZ	M37ENmNmdGxiVnnhZoltcXS7IFHzd4F6	NGnJUFIyKM7:TR?=	MVqxMVQh\A>?		NEHEU2Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>?	NEGzS\|MzPjB4N{S2OC=>
HMC-1.1	NIHwN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVO1MVUxODBibl2=	MVm0PEBp	MUXEUXNQ	Mm\SbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MoTRNlYxPTV\|MEO=
HMC-1.2	M3vMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\VWWc2NTVyMECgcm0>	MYm0PEBp	NGrhOWJFVVOR	Mn\wbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MUiyOlA2PTNyMx?=
ROSA KIT WT	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{mw[\|UuPTByMDDuUS=>	M4rTZlQ5KGh?	NWPNfIJKTE2VTx?=	MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Mn\oNlYxPTV\|MEO=
ROSA KIT D816V	MmjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXRbIVlPS13MECwJI5O	NWLBSVJ[PDhiaB?=	MWXEUXNQ	NIS2T41qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MX:yOlA2PTNyMx?=
HMC-1.1	NFnYV2tCeG:ydH;zbZMhSXO\|YYm=	M2XPOVIxOC13MECwJI5O	NH30OpA1QCCq	NH;ZeHJFVVOR	NGLScXJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MWqyOlA2PTNyMx?=
HMC-1.2	M2roO2Fxd3C2b4Ppd{BCe3OjeR?=	Mn\1NlAxNTVyMECgcm0>	MVG0PEBp	M2fIfGROW09?	MkjIbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NWDzeFM3OjZyNUWzNFM>
ROSA KIT WT	NHnI[oRCeG:ydH;zbZMhSXO\|YYm=	M{nSPFIxOC13MECwJI5O	MYm0PEBp	NY\4U5RbTE2VTx?=	Ml\NbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NF3qUJUzPjB3NUOwNy=>
ROSA KIT D816V	NWfqRppYSXCxcITvd4l{KEG\|c3H5	M3q4[lIxOC13MECwJI5O	NEPLOlY1QCCq	M3ezSWROW09?	M3vxO4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MY[yOlA2PTNyMx?=
494H	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVO3NkBp	M3vrbmROW09?	M4rEOWlEPTB;MD6xNlLDuTBwMEC0JO69VQ>?	NHTCPWczPTl2NEW2Oi=>
493H	NXLVdphOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NH7rW\|Q4OiCq	MXjEUXNQ	M1fYPGlEPTB;MD6wOFfDuTBwMEC5JO69VQ>?	MUGyOVk1PDV4Nh?=
716H	M33lTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnfKO\|IhcA>?	NIH0W4RFVVOR	NVLTUnNQUUN3ME2wMlIyOsLzMD6wN\|Qh\|ryP	NHXqcZkzPTl2NEW2Oi=>
148I	MkPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUnQOYdIPzJiaB?=	M{TPcmROW09?	NHfoVIRKSzVyPUCuNlg1yrFyLkCzOUDPxE1?	NGf6bokzPTl2NEW2Oi=>
98Sc	NVS2O4lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3rHSVczKGh?	NF7XT\|lFVVOR	NIO0T3lKSzVyPUCuNVE2yrFyLkCwOEDPxE1?	M4XifFI2QTR2NU[2
89R	M{\6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MofrO\|IhcA>?	M4PaUmROW09?	MkfxTWM2OD1yLkGyOuKyOC5yMEOg{txO	M3PCPVI2QTR2NU[2
494L	NGHVZ2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M13yb\|czKGh?	NYCxZ5htTE2VTx?=	NYj2bZVlUUN3ME2wMlMyP8LzMD6wNVIh\|ryP	MVOyOVk1PDV4Nh?=
493L	M3nofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVPVdI9xPzJiaB?=	MXjEUXNQ	NVu2fJhtUUN3ME2wMlA2OMLzMD6wNVEh\|ryP	NGjtTWwzPTl2NEW2Oi=>
148L	M2TFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1zCelczKGh?	M13FbmROW09?	MoPyTWM2OD1yLkG0OuKyOC5yMUeg{txO	MmDUNlU6PDR3Nk[=
98L	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M33CelczKGh?	MmTPSG1UVw>?	Ml7RTWM2OD1yLkOwPeKyOC5yMkmg{txO	M33vWVI2QTR2NU[2
OS17	NEHrc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{n3TlczKGh?	MY\EUXNQ	NVP6ZmVDUUN3ME2wMlA4QcLzMD6wNFMh\|ryP	NFfhS5kzPTl2NEW2Oi=>
OS9	NXfSR5dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Ml3CO\|IhcA>?	MUTEUXNQ	MXLJR\|UxRTBwNEC2xtExNjB{ODFOwG0>	NULGfGZlOjV7NES1OlY>
MG63	NULQd2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoXNO\|IhcA>?	MYHEUXNQ	MVrJR\|UxRTBwMUG0xtExNjB{NTFOwG0>	NYDqXnp7OjV7NES1OlY>
SAOS2	MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{LXbVczKGh?	NHPWT4FFVVOR	M3H3UGlEPTB;MD6yNVfDuTBwMECzJO69VQ>?	MWiyOVk1PDV4Nh?=
U2OS	NF\vVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mle0O\|IhcA>?	NY\UOI5JTE2VTx?=	M4nPOWlEPTB;MD6xPVjDuTBwMEC4JO69VQ>?	NIOxcnkzPTl2NEW2Oi=>
SJSA-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWDDWmVoPzJiaB?=	NInwR2JFVVOR	Ml;3TWM2OD1yLkGwNOKyOC5yMUCg{txO	M{e5R\|I2QTR2NU[2
494H	M2HoS2Fxd3C2b4Ppd{BCe3OjeR?=	MXWwMlI2NzBwNT:xMlAh\|ryP	NUPnPGxMOjRiaB?=	NVvYU\|diTE2VTx?=	MVLpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	NX\qOmtmOjV7NES1OlY>
148I	Mlz0RZBweHSxc3nzJGF{e2G7	NYXYZZl5OC5{NT:wMlUwOS5yIN88US=>	MVGyOEBp	NFHnU\|RFVVOR	M1\3OIlv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>?	NEL3UGozPTl2NEW2Oi=>
OS17	MWPBdI9xfG:\|aYOgRZN{[Xl?	MkfCNE4zPS9yLkWvNU4xKM7:TR?=	M4LBW\|I1KGh?	NGrMco5FVVOR	MYHpcoNz\WG\|ZYOgcIV3\Wy\|IH;mJINt\WG4ZXSgZ4F{eGG\|ZT2zxsA>	MYSyOVk1PDV4Nh?=
494H	NYe4VW1rSXCxcITvd4l{KEG\|c3H5	M{nKOFHjiIoQvF2=	NFXBXHk1QCCq	MoT1SG1UVw>?	NV;OXHlScW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6	NYD4ZpJiOjV7NES1OlY>
148I	NXv1SJo3SXCxcITvd4l{KEG\|c3H5	MUmx5qCK\|ryP	M2XOWVQ5KGh?	NU\pdotwTE2VTx?=	MnrMbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	MnTVNlU6PDR3Nk[=
OS17	MnzRRZBweHSxc3nzJGF{e2G7	MXSx5qCK\|ryP	MmC0OFghcA>?	NHjvfVhFVVOR	MlXqbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5	NUP4R2lGOjV7NES1OlY>
MOLM13	MmXURZBweHSxc3nzJGF{e2G7	M37SeFI2OCCwTR?=	NVr4S4FxPDhiaB?=	MUjEUXNQ	NIn4PZVqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m\|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK=	M3\VZ\|I2ODV\|OEK1
MV4-11	NH\Z[m1CeG:ydH;zbZMhSXO\|YYm=	MlPyNlUxKG6P	MUW0PEBp	Mo[0SG1UVw>?	M3XUd4lv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?=	NGnKT24zPTB3M{iyOS=>
MOLM13	M165emZ2dmO2aX;uJGF{e2G7	MlzrNlUxKG6P	NVTHT\|FPOjRiaB?=	MYDEUXNQ	NIDtVnZmdmijbnPld{ByfWm8YYL0bY5q[i2rbnT1Z4VlKG2xcnWgdFIyNCCESV2sJIFv\CClbHXheoVlKFCDUmC=	MnrVNlUxPTN6MkW=
MV4-11	M1\6SGZ2dmO2aX;uJGF{e2G7	MljkNlUxKG6P	MYCyOEBp	NEP6eVhFVVOR	NXzXWVRw\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ	NUPZdZkxOjVyNUO4NlU>
MOLM13	M{fyXGFxd3C2b4Ppd{BCe3OjeR?=	NXnUNG9POjVyIH7N	MX20PEBp	M4LKU2ROW09?	M2nzXolv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ?	Mnu3NlUxPTN6MkW=
MV4-11	NWDB[pN2SXCxcITvd4l{KEG\|c3H5	MWKyOVAhdk1?	NVKw[5h4PDhiaB?=	NILDVZRFVVOR	Mm\UbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>?	M1LYVVI2ODV\|OEK1
Hela	NWjze\|RjS2WubDDWbYFjcWyrdImgRZN{[Xl?	MnLNNE02ODBibl2=	NXG5XVZMPzJiaB?=	MonvSG1UVw>?	NFTXU\|Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MVWyOVAxQTJ7NR?=
HBL-1	NHS5ZoZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	Mle0NE02ODBibl2=	NYns[VJxPzJiaB?=	MYPEUXNQ	MmfJ[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M3Tlb\|I2ODB7Mkm1
HLY-1	NYTaSFdoS2WubDDWbYFjcWyrdImgRZN{[Xl?	M4XGSlAuPTByIH7N	Ml3JO\|IhcA>?	NF3yWZVFVVOR	NITBN5Nl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NGLibnEzPTByOUK5OS=>
OCI-Ly3	Mm\DR4VtdCCYaXHibYxqfHliQYPzZZk>	NGD1NGwxNTVyMDDuUS=>	M{D6Z\|czKGh?	M2TzU2ROW09?	Ml7X[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NUm1XoFuOjVyMEmyPVU>
OCI-Ly10	MlfVR4VtdCCYaXHibYxqfHliQYPzZZk>	NELq[\|AxNTVyMDDuUS=>	MlXMO\|IhcA>?	M13VfmROW09?	Mnv0[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MnHTNlUxODl{OUW=
SU-DHL-4	NIe2THpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MYCwMVUxOCCwTR?=	M{XQN\|czKGh?	MVvEUXNQ	Mmfs[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MYKyOVAxQTJ7NR?=
SU-DHL-5	NWj6W4R2S2WubDDWbYFjcWyrdImgRZN{[Xl?	NGnmNFUxNTVyMDDuUS=>	MV[3NkBp	NET2b25FVVOR	M4X2ZoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MmfLNlUxODl{OUW=
SU-DHL-6	MkDuR4VtdCCYaXHibYxqfHliQYPzZZk>	MmXzNE02ODBibl2=	M4W0SVczKGh?	MX7EUXNQ	NFu2OItl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NIHyXokzPTByOUK5OS=>
SU-DHL-10	M2jSTmNmdGxiVnnhZoltcXS7IFHzd4F6	MXywMVUxOCCwTR?=	MV63NkBp	M1OxcGROW09?	Ml;m[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NF60RVUzPTByOUK5OS=>
RC-K8	MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NG[2eY4xNTVyMDDuUS=>	M3L0R\|czKGh?	NWLIbHhjTE2VTx?=	M3;mRYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFOxcHkzPTByOUK5OS=>
OCI-Ly8	M12wb2NmdGxiVnnhZoltcXS7IFHzd4F6	MnrMNE02ODBibl2=	NU[3T5B{PzJiaB?=	MVjEUXNQ	MoDL[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MkHoNlUxODl{OUW=
OCL-Ly18	MnTVR4VtdCCYaXHibYxqfHliQYPzZZk>	M1\zTVAuPTByIH7N	NUGzbJFTPzJiaB?=	M2PNeGROW09?	Moj3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NFvXe3AzPTByOUK5OS=>
OCI-Ly3	NYXSR\|k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrHNVczNzJ3MD:1NFAhdk1?	M2fXdFIwPyCm	M1;DfGROW09?	M4jZdolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC=	NYSxWIh{OjVyMEmyPVU>
OCI-Ly8	M{DscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLZNVczNzJ3MD:1NFAhdk1?	MUOyM\|ch\A>?	Mom3SG1UVw>?	MVXpcoR2[2W\|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi	MXyyOVAxQTJ7NR?=
SU-DHL-4	NHPvRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDHUGEyPzJxMkWwM\|UxOCCwTR?=	NFnpXVczNzdiZB?=	NWHQe25XTE2VTx?=	NEXmT2xqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg	NF7uNFczPTByOUK5OS=>
SU-DHL-10	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUixO\|IwOjVyL{WwNEBvVQ>?	NISzVnMzNzdiZB?=	NVrHb2V3TE2VTx?=	NVTEfYV[cW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC\|dXKtS\|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=>	NFPL[I0zPTByOUK5OS=>
OCI-Ly3	MWDBdI9xfG:\|aYOgRZN{[Xl?	NH\oXIkyPzJxMkWwJI5O	NH61Tmw4\A>?	NG\YcnpFVVOR	NXHwdmhScW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6	MVWyOVAxQTJ7NR?=
OCI-Ly8	NILNXJVCeG:ydH;zbZMhSXO\|YYm=	MVOxO\|IwOjVyIH7N	NWTXb4g4P2R?	M3jpe2ROW09?	MVTpcoNz\WG\|ZYOgZ4F{eGG\|ZT2zM\|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm=	NVLEPXZEOjVyMEmyPVU>
SU-DHL-4	NV3BbJJoSXCxcITvd4l{KEG\|c3H5	NF70UXcyPzJxMkWwJI5O	MmnMO4Q>	M4HtemROW09?	Mk\1bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC\|aXfubYZq[2GwdHz5	MVWyOVAxQTJ7NR?=
SU-DHL-10	Ml\zRZBweHSxc3nzJGF{e2G7	MnznNVczNzJ3MDDuUS=>	Mnq0O4Q>	NIrUNIVFVVOR	NH7tN\|FqdmO{ZXHz[ZMh[2G\|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk>	NELYSngzPTByOUK5OS=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; PubMed: 26119999 Chem Biol The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. c-Myc; PubMed: 23792448 Oncogene PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. p27; PubMed: 23792448 Oncogene Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.	26119999 23792448
Growth inhibition assay	Cell viability; PubMed: 23792448 Oncogene PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control.	23792448
Immunofluorescence	GM130; PubMed: 29074567 Mol Biol Cell Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. MHC / EdU; PubMed: 28733670 Sci Rep C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.	29074567 28733670

In vivo

(+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. ^[1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. ^[2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. ^[3]

Protocol

Cell Research: ^[1]	- Collapse Cell lines: MC 11060 cells Concentrations: ~500 nM Incubation Time: 48 hours Method: Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism). (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Mice bearing NMC 797 xenografts Formulation: 5% DMSO in 5% dextrose Dosages: 50 mg/kg Administration: intraperitoneal injection (Only for Reference)

Cell Research:

^[1]

- Collapse

Cell lines: MC 11060 cells
Concentrations: ~500 nM
Incubation Time: 48 hours
Method:
Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).

(Only for Reference)

Animal Research:

^[1]

- Collapse

Animal Models: Mice bearing NMC 797 xenografts
Formulation: 5% DMSO in 5% dextrose
Dosages: 50 mg/kg
Administration: intraperitoneal injection
(Only for Reference)

References

[4] Li Z, et al. Nucleic Acids Res, 2013, 41(1), 277-287.

- Collapse

Solubility (25°C)

In vitro	DMSO	91 mg/mL warmed (199.12 mM)
	Ethanol	91 mg/mL (199.12 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download (+)-JQ1 SDF

Molecular Weight	456.99
Formula	C₂₃H₂₅ClN₄O₂S
CAS No.	1268524-70-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How can I reconstitute the compound for in vivo injection?
Answer:
JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Pan BET Inhibitor

Bromosporine : Pan-BET inhibitor, BRD2, IC50=0.41 μM; BRD4, IC50=0.29 μM; BRD9, IC50=0.122 μM; CECR2, IC50=0.017 μM.
BET Inhibitor in Clinical Trial

RVX-208 ^New : Phase II for Dyslipidemia.
Newest BET Inhibitor

I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.
Classic BET Inhibitor

I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1

Cited by 70 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download (+)-JQ1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Choose Your Country or Region

By Signaling Pathways

By product type

(+)-JQ1

Cited by 70 Publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download (+)-JQ1 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)